Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Welcome to Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience


Find the latest content and information here about the 2019 Charles Schwab Impact Conference.


Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Fidelity Investments logo


Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Shauna O'Brien Feb 25, 2015

There have been a few industries that have been outperforming the S&P 500 since the beginning of 2015 – one of them being the biotechnology industry. While this run is nothing new, it is notable to mention that this industry is off to a good start for the year. This week, we have chosen the Fidelity® Select Biotechnology Fund (fbiox) as our fund of the week.

Inside the Fund

The fund was launched in 1985 and is managed by Rajiv Kaul. Currently, it has about $12 billion in assets under management (AUM). This fund is composed of healthcare companies of all sizes. The majority of these companies are based in the United States.

So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.

Historical Performance

Largest Holdings

Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.

The Bottom Line

The biotechnology industry is an industry that many aggressive investors have kept a close eye on over the years. Investors seeking exposure to the industry may consider a mutual fund like the Fidelity® Select Biotechnology (fbiox).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book